Omega-3 polyunsaturated fatty acids when administered to lactating rats modify the development of experimental anxiety-depressive state in the rat pups exposed to the dipeptidyl peptidase-iv inhibitor diprotin a on the second – third weeks after the birth
Abstract
Background. Omega-3 polyunsaturated fatty acids (PUFAs) belong to the hypolipidemic drugs, exhibit antioxidant properties and are used in the clinic for secondary prevention of several diseases. The effects of omega-3 PUFAs on the course of the stress-induced and endogenous depression are under investigation. We have previously demonstrated that synthetic inhibitors of prolyl endopeptidase (PEP; EC 3.4.21.26) exhibit antidepressant-like properties in different experimental models of emotional and motivational disorders. It is known that omega-3 PUFAs show PEP inhibitory activity. Purpose. The purpose of this work was to study the effects of the drug Omacor (Abbot, Germany) containing omega-3 PUFAs, when administered to the lactating Wistar rats, on the emotional and motivational behavior of the offspring with the experimental anxiety-depressive disorder caused by the inhibitor of dipeptidyl peptidase IV (DPP- IV; CD 26; EC 3.4.14.5) diprotin on postnatal day (PND) 5‒18 (second – third weeks of postnatal development). Methods. We used conventional methods of assessing the emotional and motivational behavior and sensorimotor reactivity in animals. Omega-3 PUFAs were administered to lactating rats at a dose 0.3 g / kg, per os, for 28 days starting from the next day after the birthing. Diprotin A was administered systemically at a dose of 2 mg/kg. Results. Omega-3 PUFAs when administered to the lactating females, prevented the development of depressive-like behavior in adolescent rats neonatally exposed to DPP-IV inhibitor diprotin A, and contributed to the formation of antidepressive phenotype in control rats. However, under these circumstances, the omega-3 PUFAs increased anxiety and did not prevent an increase in aggression in rats with the experimental anxiety-depressive disorder and increased anxiety and stress-provoked aggression in the controls. Conclusion. The results support the hypothesis on the involvement of proline-specific peptidases DPP-IV and PEP in the mechanisms of emotional and motivational disturbances and expand the spectrum of omega-3 PUFAs action.
Downloads
References
2 Walz C.P., Barry A.R., Koshman S.L. Omega-3 polyunsaturated fatty acid supplementation in the prevention of cardiovascular disease. Can. Pharm. J. (Ott). 2016; May;149(3):166-73. doi: 10.1177/1715163516640812.
3 Backes J., Anzalone D., Hilleman D., Catini J. The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia. Lipids Health Dis. 2016; Jul 22;15(1):118. doi: 10.1186/s12944-016-0286-4.
4 Sala-Vila A, Díaz-López A., Valls-Pedret C., Cofán M., García-Layana A., Lamuela-Raventós R.M., Castañer O., Zanon-Moreno V., Martinez-Gonzalez M.A., Toledo E., Basora J., Salas-Salvadó J., Corella D., Gómez-Gracia E., Fiol M., Estruch R., Lapetra J., Fitó M., Arós F., Serra-Majem L., Pintó X., Ros E., Prevención con Dieta Mediterránea (PREDIMED) Investigators. Dietary Marine ω-3 Fatty Acids and Incident Sight-Threatening Retinopathy in Middle-Aged and Older Individuals With Type 2 Diabetes: Prospective Investigation From the PREDIMED Trial. JAMA Ophthalmol. 2016; Aug 18. doi: 10.1001/jamaophthalmol.2016.2906.
5 Pusceddu M.M., Kelly P., Stanton C., Cryan J.F., Dinan T.G. N-3 Polyunsaturated Fatty Acids through the Lifespan: Implication for Psychopathology. Int. J. Neuropsychopharmacol. 2016; Sep 21. pii: pyw078. doi: 10.1093/ijnp/pyw078.
6 Carlson S.J., Fallon E.M., Kalish B.T., Gura K.M., Puder M. The role of the ω-3 fatty acid DHA in the human life cycle. JPEN J. Parenter. Enteral. Nutr. 2013; 37(1):15-22. doi:10.1177/0148607112467821.
7 Larrieu T., Hilal M.L., Fourrier C., De Smedt-Peyrusse V., Sans N., Capuron L., Layé S. Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion. Transl. Psychiatry. 2014; 4:e437. doi: 10.1038/tp.2014.77.
8 Park Y.M., Lee B.H., Lee S.H. The association between serum lipid levels, suicide ideation, and central serotonergic activity in patients with major depressive disorder. J. Affect. Disord. 2014; 159: 62-6. doi: 10.1016/j.jad.2014.01.016.
9 Appleton K.M., Grippo A.J., Beltz T.G., Johnson A.K. Consumption of a high n-3 polyunsaturated fatty acid diet during gradual mild physiological stress in rats. Prostaglandins Leukot. Essent. Fatty Acids. 2015; 95:11-8. doi: 10.1016/j.plefa.2014.11.010.
10 Park Y.S., Jang H.J., Lee K.H., Hahn T.R., Paik Y.S. Prolyl endopeptidase inhibitory activity of unsaturated fatty acids. J. Agric. Food. Chem. 2006; 54(4): 1238-42.
11 Khlebnikova N.N., Krupina N.A., Orlova I.N., Bogdanova N.G., Zolotov N.N., Kryzhanovskii G.N. Effect of a prolyl endopeptidase inhibitor benzyloxycarbonyl-alanyl-proline on the development of experimental depressive syndrome in rats. Bull. Exp. Biol. Med. 2009; 147(3): 291–5. DOI 10.1007/s10517-009-0494-2
12 Khlebnikova N.N., Krupina N.A., Kushnareva E.Yu., Zolotov N.N., Kryzhanovskii G.N. Effect of imipramine and prolyl endopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine on activity of proline-specific peptidases in the brain of rats with experimental anxious-depressive syndrome. Bull. Exp. Biol. Med. 2012; 152(4): 409-12. DOI: 10.1007/s10517-012-1540-z
13 Krupina N. A., Bogdanova N. G., Khlebnikova N. N., Zolotov N. N., Kryzhanovskii G. N. Benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine, a prolyl endopeptidase inhibitor, modulates depression-like behavior of rats in forced swimming test and activities of proline-specific peptidases in the brain structures. Bull. Exp. Biol. Med. 2013; 154(5): 606-9. DOI: 10.1007/s10517-013-2010-y
14 Khlebnikova N.N., Krupina N.A., Bogdanova N.G., Orlova I.N., Zolotov N.N. Effect of prolyl endopeptidase inhibitor benzyloxycarbonyl-methionyl-2(S)-cyanopyrrolidine on the course of experimental depressive syndrome in rats. Bull. Exp. Biol. Med. 2013; 155(2): 190-3. DOI 10.1007/s10517-013-2109-1
15 Krupina N.A., Khlebnikova N.N. Neonatal exposure to the dipeptidyl peptidase-IV inhibitors diprotin A and sitagliptin induces depression-like behavior, anxiety, and latent aggression in adolescent and adult rats. J. Behav. Brain Sci. 2016; 6(4): 167-83. http://dx.doi.org/10.4236/jbbs.2016.64018
16 Gus'kova T.A. Preclinical toxicological study of drugs as a guarantee of their safe clinical investigations. Toksikol. Vestnik. 2010; 5: 2-5. (in Russian)
17 Kanji S., Seely D., Yazdi F., Tetzlaff J., Singh K., Tsertsvadze A., Tricco A.C., Sears M.E., Ooi T.C., Turek M.A., Skidmore B., Ansari M.T. Interactions of commonly used dietary supplements with cardiovascular drugs: a systematic review. Syst. Rev. 2012; 1:26. doi: 10.1186/2046-4053-1-26.
18 O’Leary, T.P., Gunn, R.K. and Brown, R.E. What are we measuring when we test strain differences in anxiety in mice? Behav. Genetics. 2013; 43: 34-50.
19 Krupina N.A., Khlebnikova N.N., Orlova I.N. Early social isolation increases aggression and impairs a short-term habituation in acoustic startle reflex in rats. Patol. Fiziol. Eksp. Ter. 2015; 59(4): 4-15. (in Russian)
20 Valsamis B., Schmid S. Habituation and prepulse inhibition of acoustic startle in rodents. J. Vis. Exp. 2011; (55): e3446. doi: 10.3791/3446.
21 Huang Shih-Yi, Yang Hui-Ting, Chiu Chih-Chiang, Pariante Carmine M., Su Kuan-Pin. Omega-3 fatty acids on the forced-swimming test. J. Psychiatr. Res. 2008; 42: 58–63.
22 Kushnareva E.Yu., Krupina N.A., Khlebnikova N.N., Zolotov N.N., Kryzhanovskii G.N. Activities of proline-specific peptidases in brain structures of rats with experimental anxiety-depressive state caused by administration of dipeptidyl peptidase IV inhibitor in the early postnatal period. Bull. Exp. Biol. Med. 2011; 151(6): 675-9, DOI: 10.1007/s10517-011-1413-x
23 Krupina N. A., Zubkov E.A., Orshanskaya E.V., Zorkina Y.A., Khlebnikova N.N. Gene expression in the brain of adult rats with behavioral alterations caused by neonatal exposure to the dipeptidyl peptidase-IV inhibitors diprotin A and sitagliptin. Eur. Neuropsychopharmacol. 2016; 26(Suppl. 2):
